This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Barich, L. L. Articles by Barich, D. Search for Related Content PubMed PubMed Citation Articles by Barich, L. L. Articles by Barich, D.

Oral Griseofulvin: A Cocarcinogenic Agent to Methylcholanthrene-induced Cutaneous Tumors^*

( Clinical Laboratories, Jewish Hospital, Cincinnati; and Departments of Dermatology and Pathology, College of Medicine, University of Cincinnati, Cincinnati, Ohio)

Since certain antitumor drugs also arrest mitosis in metaphase, an attempt was made to determine the effect of oral griseofulvin on methylcholanthrene-induced cutaneous tumors in mice. Contrary to expectations, mice on large doses (1000–1500 mg/kg) of griseofulvin subjected to methylcholanthrene applications had a shorter tumor lag period and developed more and larger tumors than did mice not receiving griseofulvin but receiving similar amounts of methylcholanthrene. A cocarcinogenic effect was also noted in mice that received lower doses (10–15 mg/kg) of griseofulvin for 6 weeks prior to, during, and subsequent to methylcholanthrene applications, but not in mice that received this dosage for 4 weeks prior to, during, and subsequent to methylcholanthrene application.

^* This study was supported in part by grants from the National Institutes of Health (CY-5071 and 5368), McNeil Laboratories, Inc., the Schering Corporation, and the American Research Foundation.

Received 7/19/61.